Dexcom (NASDAQ: DXCM) shares 2025 preview, 2026 financial outlook update

Rhea-AI Filing Summary

Dexcom, Inc. is providing an early look at its recent performance and plans. In remarks at the J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026, President and CEO Jake Leach will present preliminary, unaudited financial results for the fourth quarter and full year 2025, along with an initial financial outlook for 2026 and other business information.

The company issued a press release on January 12, 2026 with these preliminary results and outlook, attached as Exhibit 99.1, and a separate business update press release on January 7, 2026, attached as Exhibit 99.2. Dexcom notes that the preliminary figures are subject to finalization during preparation of its Annual Report on Form 10-K and that the information in these materials is being furnished, not filed, under securities law.

false000109355700010935572026-01-072026-01-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 7, 2026

DEXCOM, INC.

(Exact Name of the Registrant as Specified in Its Charter)

Delaware			000-51222			33-0857544
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

6340 Sequence Drive, San Diego, CA						92121
(Address of Principal Executive Offices)						(Zip Code)

(858) 200-0200

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, $0.001 Par Value Per Share

DXCM

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

In connection with remarks to be made at the J.P. Morgan 44th Annual Healthcare Conference on Monday, January 12, 2026, beginning at 10:30 a.m. (Eastern Time), DexCom, Inc. (“Dexcom”) President and Chief Executive Officer, Jake Leach, will report preliminary, unaudited financial results for the fourth quarter of 2025 and fiscal year 2025, initial financial outlook for fiscal year 2026, and certain other information.

The fourth quarter and fiscal year 2025 preliminary unaudited financial results contained in Mr. Leach’s presentation, the press release and this Current Report on Form 8-K are subject to finalization in connection with the preparation of Dexcom’s Annual Report on Form 10-K for the twelve months ended December 31, 2025. This Current Report on Form 8-K and the press release contain, and Mr. Leach’s presentation on January 12, 2026 will contain, forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to Dexcom’s preliminary, unaudited revenue for the fourth quarter of and the full fiscal year 2025, including growth rates; total revenue guidance for fiscal 2026; Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin guidance for fiscal 2025 and 2026, including expected growth rates; and potential strategic and business opportunities. All forward-looking statements included in Mr. Leach’s presentation, the press release and in this Current Report on Form 8-K are made as of the date published, based on information currently available to Dexcom as of the date hereof. Forward-looking statements deal with future events and therefore are subject to various risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Dexcom’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. Should one or more of these risks or uncertainties materialize, or should any of Dexcom’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.

In connection with Mr. Leach’s presentation, on January 12, 2026, Dexcom issued a press release announcing preliminary, unaudited results for the fourth quarter of 2025 and fiscal year 2025, initial financial outlook for fiscal year 2026, and certain other information, which is attached here as Exhibit 99.1.

Additionally, on January 7, 2026, Dexcom issued a press release providing a business update, which is attached here as Exhibit 99.2.

The information in this Item 2.02, including Exhibits 99.1 and 99.2 hereto, is furnished shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of Dexcom under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01.    FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Number						Description
99.1						Press release dated January 12, 2026
99.2						Press release dated January 7, 2026
104						Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DEXCOM, INC.
By:						/s/ JEREME M. SYLVAIN Jereme M. Sylvain Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)
Date:						January 12, 2026

FAQ

What does Dexcom (DXCM) disclose in this 8-K?

Dexcom reports that its CEO, Jake Leach, will present preliminary, unaudited financial results for the fourth quarter and full year 2025, an initial financial outlook for 2026, and other information at the J.P. Morgan 44th Annual Healthcare Conference.

Which periods are covered by Dexcom’s preliminary financial results in this update?

The preliminary, unaudited results cover Dexcom’s fourth quarter of 2025 and its full fiscal year 2025, with an initial financial outlook provided for fiscal year 2026.

What press releases are attached to Dexcom’s (DXCM) current report?

Dexcom attaches two exhibits: Exhibit 99.1 is a press release dated January 12, 2026 with preliminary 2025 results and 2026 outlook, and Exhibit 99.2 is a business update press release dated January 7, 2026.

How does Dexcom classify the information in this 8-K under securities law?

Dexcom states that the information in Item 2.02 and Exhibits 99.1 and 99.2 is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or incorporated by reference into other filings, except where specifically referenced.

What forward-looking information does Dexcom (DXCM) reference in this update?

Dexcom references forward-looking statements related to preliminary unaudited revenue for the fourth quarter and full year 2025, total revenue guidance for 2026, Non-GAAP gross profit margin and operating margin guidance for 2025 and 2026, and potential strategic and business opportunities.

When and where will Dexcom’s CEO present the preliminary 2025 results?

Jake Leach will present the preliminary results and 2026 outlook on Monday, January 12, 2026, beginning at 10:30 a.m. Eastern Time at the J.P. Morgan 44th Annual Healthcare Conference.